WG1:

Manufacturing, scale-up, standardization and quality control

WG1 focuses on harmonising CAR-T manufacturing processes across Europe. The group will develop shared Standard Operating Procedures (SOPs), quality-control guidelines, and release criteria to ensure consistency and safety across centres. WG1 will also address scale-up challenges, identify cost-efficient production strategies, and build new collaborative research projects aimed at improving manufacturing efficiency and affordability.

WG2:

Preclinical development of novel CAR-T therapies

WG2 promotes innovation in next-generation CAR-T therapies. The group will review emerging technologies, develop guidelines for preclinical testing, and support collaborative projects exploring new CAR designs, improved T-cell engineering approaches, and strategies to enhance efficacy and safety. WG2 brings together scientific and clinical expertise to accelerate early-stage development of novel CAR-T products.

WG3:

Regulatory affairs and market access

WG3 works to streamline regulatory pathways and improve access to CAR-T therapies across Europe. The group will develop common regulatory guidelines, perform market analyses to identify barriers to access, and engage with authorities and policymakers. WG3 supports harmonisation of approval processes, advocacy for fair pricing and reimbursement, and integration of CAR-T therapies into national healthcare systems.

WG4:

Clinical research

WG4 focuses on advancing clinical knowledge and improving patient outcomes. The group will develop best-practice clinical management guidelines, promote the integration of biomarkers for patient stratification, and facilitate data sharing across centres. Through expert meetings, workshops, and collaborative clinical research, WG4 aims to harmonise clinical practices and improve understanding of efficacy, toxicity, and variability in patient responses.

WG5:

Public awareness and patient engagement

WG5 works to increase understanding of CAR-T therapies among patients, caregivers, and the general public. The group will create educational materials and coordinate outreach events across Europe. WG5 ensures that patients’ perspectives are integrated into research efforts and that communication is clear, accessible, and impactful.

WG6:

Training and dissemination

WG6 leads capacity building across the network by organising training schools, workshops, conferences, and short-term scientific missions (STSMs). It ensures participation of young researchers and innovators through mentorship programmes and targeted support. WG6 also manages website content, communication strategy, and dissemination of outputs, ensuring that CINNAMON’s achievements reach the scientific community, stakeholders, policymakers, and the public.